ALX Oncology Holdings Inc (ALXO) shareholders
Close on Nov 18, 2026Market cap $134.14MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| RA Capital Healthcare Fund, L.P. Joint filing with RA Capital Management, L.P. (9.90%), Peter Kolchinsky (9.90%) and 1 more | 13,117,106 | 9.90% | 13G (passive) | Feb 2, 2026 |
| Goodman Corey S Joint filing with venBio Global Strategic Fund II L.P. (6.50%), venBio Global Strategic GP II, L.P. (6.50%) and 1 more | 12,927,442 | 9.99% | 13D (active) amendment | Oct 14, 2026 |
| Redmile Group, LLC Joint filing with Jeremy C. Green (6.80%) | 9,214,188 | 6.80% | 13G (passive) amendment | Mar 31, 2026 |
| HBM Healthcare Investments (Cayman) Ltd. | 8,590,692 | 6.50% | 13G (passive) amendment | Mar 31, 2026 |
| BlackRock, Inc. | 7,327,850 | 5.40% | 13G (passive) | Jun 30, 2026 |
| Tang Capital Partners, LP Joint filing with Tang Capital Management, LLC (6.30%), Kevin Tang (6.30%) | 3,296,883 | 6.30% | 13G (passive) amendment | Dec 31, 2024 |
| Millennium Management LLC Joint filing with Millennium Group Management LLC (6.00%), Israel A. Englander (6.00%) and 1 more | 3,188,196 | 6.00% | 13G (passive) amendment | Oct 17, 2025 |
| Kevin Tang Joint filing with Tang Capital Management, LLC (5.90%) | 3,158,265 | 5.90% | 13G (passive) amendment | Mar 31, 2025 |
| Millennium Group Management LLC Joint filing with Millennium Management LLC (5.10%), Israel A. Englander (5.10%) | 2,707,151 | 5.10% | 13G (passive) | Oct 2, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ALXO | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 13,011,849 | 9.41% | $26.93M | – | 0.23% |
| venBio Partners LLC | 12,884,638 | 9.32% | $26.67M | – | 5.14% |
| BlackRock, Inc. | 7,399,530 | 5.35% | $15.32M | +6,951,731 | 0.00% |
| Redmile Group, LLC | 7,392,504 | 5.35% | $15.30M | −571,684 | 1.03% |
| Blackstone Inc. | 6,593,543 | 4.77% | $13.65M | +766,999 | 0.04% |
| Driehaus Capital Management LLC | 6,025,240 | 4.36% | $12.47M | +290,620 | 0.07% |
| Silverarc Capital Management, LLC | 5,744,757 | 4.15% | $11.89M | New | 1.24% |
| TCG Crossover Management, LLC | 5,655,487 | 4.09% | $11.71M | −7,356,362 | 0.28% |
| Vanguard Capital Management LLC | 4,973,436 | 3.60% | $10.30M | +793,700 | 0.00% |
| Vivo Capital, LLC | 3,184,713 | 2.30% | $6.59M | – | 0.60% |
| Marshall Wace, Llp | 3,071,496 | 2.22% | $6.36M | −685,720 | 0.01% |
| 5AM Venture Management, LLC | 3,057,325 | 2.21% | $6.33M | – | 2.20% |
| Almitas Capital LLC | 2,938,431 | 2.13% | $6.08M | −235,403 | 1.46% |
| Orbimed Advisors LLC | 2,866,256 | 2.07% | $5.93M | – | 0.11% |
| Geode Capital Management, LLC | 2,787,809 | 2.02% | $5.77M | +2,294,372 | 0.00% |
| Two Sigma Investments, LP | 2,178,176 | 1.58% | $4.51M | +590,343 | 0.00% |
| Millennium Management LLC | 1,543,594 | 1.12% | $3.20M | −444,965 | 0.00% |
| Nantahala Capital Management, LLC | 1,500,000 | 1.08% | $3.11M | New | 0.05% |
| State Street Corp | 1,498,905 | 1.08% | $3.10M | +1,323,077 | 0.00% |
| Acadian Asset Management LLC | 1,313,490 | 0.95% | $2.71M | +212,465 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 94 | 106M | 76.6% | 37 / 29 | 10 / 11 | 27M | 16M |
| Q1 2026 | 69 | 94M | 68.2% | 25 / 18 | 12 / 12 | 70M | 3M |
| Q4 2025 | 57 | 29M | 21.1% | 8 / 19 | 15 / 10 | 3M | 4M |
| Q3 2025 | 61 | 30M | 22.0% | 8 / 10 | 31 / 8 | 7M | 5M |
| Q2 2025 | 61 | 29M | 21.0% | 10 / 9 | 32 / 34 | 2M | 8M |
| Q1 2025 | 85 | 35M | 25.2% | 8 / 26 | 30 / 9 | 2M | 8M |
| Q4 2024 | 87 | 41M | 29.7% | 21 / 32 | 20 / 26 | 8M | 13M |
| Q3 2024 | 92 | 46M | 32.9% | 18 / 40 | 21 / 36 | 12M | 12M |
| Q2 2024 | 112 | 49M | 35.2% | 31 / 37 | 27 / 23 | 9M | 7M |
| Q1 2024 | 106 | 47M | 33.6% | 23 / 29 | 30 / 10 | 3M | 3M |
| Q4 2023 | 93 | 46M | 33.4% | 32 / 33 | 16 / 14 | 16M | 3M |
| Q3 2023 | 76 | 33M | 24.1% | 12 / 23 | 22 / 10 | 1M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
59 funds held ALXO in Q2 2026, 80% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of ALXO | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3,642,854 | 2.63% | $7.54M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,598,748 | 1.88% | $5.38M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,174,485 | 0.85% | $2.28M | 0.01% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 1,164,899 | 0.84% | $2.41M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 1,013,254 | 0.73% | $2.10M | 0.01% | Jun 30, 2026 |
| JPMorgan U.S. Small Company Fund | 393,960 | 0.28% | $815.50K | 0.07% | Jun 30, 2026 |
| iShares Micro-Cap ETF | 361,777 | 0.26% | $748.88K | 0.05% | Jun 30, 2026 |
| Schwab Small-Cap Index Fund | 260,212 | 0.19% | $504.81K | 0.01% | Jul 31, 2026 |
| Ultra-Small Company Market Fund | 211,000 | 0.15% | $436.77K | 0.29% | Jun 30, 2026 |
| Master Small Cap Index Series | 201,688 | 0.15% | $417.49K | 0.01% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 187,907 | 0.14% | $357.02K | 0.00% | May 31, 2026 |
| U.S. Small Cap Equity Fund | 146,676 | 0.11% | $284.55K | 0.03% | Jul 31, 2026 |
| Nuveen Small Cap Blend Index Fund | 143,645 | 0.10% | $278.67K | 0.01% | Jul 31, 2026 |
| EQ/2000 Managed Volatility Portfolio | 115,694 | 0.08% | $239.49K | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Growth Index Fund | 100,498 | 0.07% | $208.03K | 0.01% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jason Lettmann | CHIEF EXECUTIVE OFFICER, Director | 2,393,474 | 1.73% | Aug 18, 2026 |
| Shelly Wong | SVP, FINANCE AND CAO | 87,828 | 0.06% | Aug 18, 2026 |
| Barbara Klencke | Chief Medical Officer | 120,000 | 0.09% | Apr 17, 2026 |
| Jeff E. Knight | Chief Dev & Operating Officer | – | – | Apr 17, 2026 |
| Harish Shantharam | Chief Financial Officer | 75,000 | 0.05% | Jan 28, 2026 |
| Jaume Pons | PRESIDENT & CSO | 579,388 | 0.42% | Feb 21, 2025 |
| Corey S. Goodman | Director, 10% owner | 8,453,038 | 6.11% | Feb 4, 2026 |
| Rekha Hemrajani | Director | 33,000 | 0.02% | Jan 21, 2026 |
| J. Scott Garland | Director | – | – | Jan 21, 2026 |
| Alan B. Sandler | Director | – | – | Jan 21, 2026 |
| Daniel J. Curran | Director | – | – | Jan 21, 2026 |
| Chris H. Takimoto | Director | – | – | Jan 21, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Shelly Wong SVP, FINANCE AND CAO | Aug 17, 2026 | Sale | −573 | $1.93 | $1.11K | 87,828 |
| Jason Lettmann CHIEF EXECUTIVE OFFICER, Director | Aug 17, 2026 | Sale | −2,230 | $1.93 | $4.30K | 294,379 |
| Shelly Wong SVP, FINANCE AND CAO | Jul 1, 2026 | Sale | −1,404 | $2.04 | $2.86K | 88,401 |
| Shelly Wong SVP, FINANCE AND CAO | Mar 19, 2026 | Sale | −903 | $2.17 | $1.96K | 86,805 |
| Jason Lettmann CHIEF EXECUTIVE OFFICER, Director | Mar 19, 2026 | Sale | −12,311 | $2.17 | $26.71K | 293,609 |
| Shelly Wong SVP, FINANCE AND CAO | Feb 18, 2026 | Sale | −565 | $2.27 | $1.28K | 87,708 |
| Jason Lettmann CHIEF EXECUTIVE OFFICER, Director | Feb 17, 2026 | Tax withholding | −2,201 | $2.27 | $5.00K | 305,920 |
| Corey S. Goodman Director, 10% owner | Feb 2, 2026 | Buy | +3,184,713 | $1.57 | $5.00M | 8,453,038 |
| Shelly Wong SVP, FINANCE AND CAO | Jan 6, 2026 | Sale | −3,925 | $1.11 | $4.36K | 88,273 |
| Jason Lettmann CHIEF EXECUTIVE OFFICER, Director | Sep 17, 2025 | Buy | +71,163 | $1.08 | $76.86K | 305,121 |
| Jason Lettmann CHIEF EXECUTIVE OFFICER, Director | Sep 16, 2025 | Buy | +21,070 | $1.07 | $22.54K | 233,958 |
| Harish Shantharam Chief Financial Officer | Aug 18, 2025 | Buy | +75,000 | $0.78 | $58.50K | 75,000 |
| Jason Lettmann CHIEF EXECUTIVE OFFICER, Director | Aug 15, 2025 | Sale | −2,382 | $0.64 | $1.52K | 212,888 |
| Shelly Wong SVP, FINANCE AND CAO | Aug 15, 2025 | Sale | −611 | $0.64 | $391 | 89,198 |
| Shelly Wong SVP, FINANCE AND CAO | Jul 7, 2025 | Sale | −2,011 | $0.45 | $905 | 86,809 |
| Shelly Wong SVP, FINANCE AND CAO | Jun 30, 2025 | Sale | −1,532 | $0.43 | $659 | 88,820 |
| Jason Lettmann CHIEF EXECUTIVE OFFICER, Director | Mar 14, 2025 | Award | +42,000 | – | – | 212,270 |
| Shelly Wong SVP, FINANCE AND CAO | Mar 14, 2025 | Award | +3,000 | – | – | 90,352 |
| Shelly Wong SVP, FINANCE AND CAO | Feb 19, 2025 | Sale | −550 | $1.15 | $633 | 87,352 |
| Jaume Pons PRESIDENT & CSO | Feb 19, 2025 | Sale | −1,326 | $1.15 | $1.52K | 579,388 |
| Jason Lettmann CHIEF EXECUTIVE OFFICER, Director | Feb 19, 2025 | Sale | −2,159 | $1.15 | $2.48K | 170,270 |
| Shelly Wong Interim CFO | Jan 6, 2025 | Sale | −2,221 | $1.80 | $4.00K | 87,902 |
| Shelly Wong Interim CFO | Dec 30, 2024 | Sale | −1,426 | $1.58 | $2.25K | 90,123 |
| Jaume Pons PRESIDENT & CSO | Dec 30, 2024 | Sale | −10,796 | $1.58 | $17.06K | 580,714 |
| Rekha Hemrajani Director | Dec 2, 2024 | Buy | +30,000 | $1.55 | $46.50K | 33,000 |
| Jaume Pons PRESIDENT & CSO | Aug 14, 2024 | Sale | −1,937 | $2.58 | $5.00K | 591,510 |
| Shelly Wong SVP, FINANCE AND CAO | Aug 14, 2024 | Sale | −564 | $2.58 | $1.46K | 91,549 |
| Sophia Randolph CHIEF MEDICAL OFFICER | Aug 14, 2024 | Sale | −1,365 | $2.58 | $3.52K | 325,711 |
| Jason Lettmann CHIEF EXECUTIVE OFFICER, Director | Aug 14, 2024 | Tax withholding | −2,191 | $2.58 | $5.65K | 169,429 |
| Peter S. Garcia CHIEF FINANCIAL OFFICER | Aug 14, 2024 | Tax withholding | −761 | $2.58 | $1.96K | 121,516 |
| Jaume Pons PRESIDENT & CSO, Director | Jul 11, 2024 | Option exercise | +20,000 | $0.99 | $19.80K | 613,447 |
| Jaume Pons PRESIDENT & CSO, Director | Jul 11, 2024 | Sale(10b5-1 plan) | −20,000 | $7.90 | $158.00K | 593,447 |
| Shelly Wong SVP, FINANCE AND CAO | Jul 5, 2024 | Sale | −1,823 | $5.50 | $10.03K | 92,113 |
| Shelly Wong SVP, FINANCE AND CAO | Jul 1, 2024 | Sale | −1,373 | $5.82 | $7.99K | 93,936 |
| Jaume Pons PRESIDENT & CSO, Director | Jul 1, 2024 | Sale | −10,758 | $5.82 | $62.61K | 593,447 |
| Sophia Randolph CHIEF MEDICAL OFFICER, Director | Jul 1, 2024 | Sale | −3,273 | $5.82 | $19.05K | 327,076 |
| Peter S. Garcia CHIEF FINANCIAL OFFICER | Jun 28, 2024 | Tax withholding | −1,789 | $6.03 | $10.79K | 122,277 |
| Peter S. Garcia CHIEF FINANCIAL OFFICER | Jun 13, 2024 | Buy | +12,000 | $8.53 | $102.36K | 122,348 |
| Peter S. Garcia CHIEF FINANCIAL OFFICER | Jun 13, 2024 | Buy | +12,000 | $8.53 | $102.36K | 122,348 |
| Jaume Pons PRESIDENT & CSO, Director | Jun 4, 2024 | Sale(10b5-1 plan) | −20,000 | $8.43 | $168.60K | 604,205 |
| Jaume Pons PRESIDENT & CSO, Director | Jun 4, 2024 | Option exercise | +20,000 | $0.99 | $19.80K | 624,205 |
| Sophia Randolph CHIEF MEDICAL OFFICER, Director | May 13, 2024 | Sale(10b5-1 plan) | −1,797 | $16.67 | $29.96K | 330,349 |
| Sophia Randolph CHIEF MEDICAL OFFICER, Director | May 13, 2024 | Sale(10b5-1 plan) | −10,203 | $15.82 | $161.41K | 332,146 |
| Jaume Pons PRESIDENT & CSO, Director | May 6, 2024 | Sale(10b5-1 plan) | −20,000 | $15.92 | $318.40K | 604,205 |
| Jaume Pons PRESIDENT & CSO, Director | May 6, 2024 | Option exercise | +20,000 | $0.99 | $19.80K | 624,205 |
| Jaume Pons PRESIDENT & CSO, Director | Apr 16, 2024 | Sale(10b5-1 plan) | −50,000 | $14.20 | $710.00K | 604,205 |
| Jaume Pons PRESIDENT & CSO, Director | Apr 16, 2024 | Option exercise | +25,846 | $0.99 | $25.59K | 654,205 |
| Jaume Pons PRESIDENT & CSO, Director | Apr 4, 2024 | Sale(10b5-1 plan) | −20,000 | $11.15 | $223.00K | 628,359 |
| Jason Lettmann CHIEF EXECUTIVE OFFICER, Director | Mar 14, 2024 | Buy | +4,400 | $11.31 | $49.76K | 171,620 |
| Sophia Randolph CHIEF MEDICAL OFFICER, Director | Feb 14, 2024 | Award | +30,000 | – | – | 342,349 |
| Jaume Pons PRESIDENT & CSO, Director | Feb 14, 2024 | Award | +30,000 | – | – | 648,359 |
| Shelly Wong SVP, FINANCE AND CAO | Feb 14, 2024 | Award | +15,000 | – | – | 93,591 |
| Jason Lettmann CHIEF EXECUTIVE OFFICER, Director | Feb 14, 2024 | Award | +60,000 | – | – | 167,220 |
| Peter S. Garcia CHIEF FINANCIAL OFFICER | Feb 14, 2024 | Award | +25,000 | – | – | 110,348 |
| Shelly Wong SVP, Finance and CAO | Jan 4, 2024 | Sale | −2,717 | $13.60 | $36.95K | 78,591 |
| Peter S. Garcia Chief Financial Officer | Dec 29, 2023 | Sale | −1,893 | $15.04 | $28.47K | 85,348 |
| Shelly Wong SVP, Finance and CAO | Dec 29, 2023 | Sale | −1,631 | $15.04 | $24.53K | 81,308 |
| Sophia Randolph Chief Medical Officer, Director | Dec 29, 2023 | Sale | −3,128 | $15.04 | $47.05K | 312,349 |
| Jaume Pons President & CSO, Director | Dec 29, 2023 | Sale | −7,179 | $15.04 | $107.97K | 618,359 |
| Shelly Wong SVP, Finance and CAO | Jul 25, 2023 | Award | +26,000 | – | – | 81,713 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of ALX Oncology's stock actually held short. Settlement fails (shares not delivered on time) peaked at 14,854 shares on Sep 2, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Jaume Pons Officer | Jul 11, 2024 | 20,000 | $135.20K | Jul 11, 2024 | Options Grant |
| Jaume Pons Officer | Jun 4, 2024 | 20,000 | $179.20K | Jun 4, 2024 | Options Grant |
| Sophia Randolph Officer | May 13, 2024 | 78,000 | $1.26M | May 13, 2024 | Restricted stock |
| Jaume Pons Officer | May 6, 2024 | 20,000 | $307.20K | May 6, 2024 | Options Grant |
| Jaume Pons Officer | Apr 16, 2024 | 50,000 | $644.50K | Apr 16, 2024 | Options Grant |
| Jaume Pons Officer | Apr 4, 2024 | 20,000 | $216.00K | Apr 4, 2024 | Restricted Stock from Option Exercise |
See a number that looks wrong?